Skip to content

Advertisement

  • Poster Presentation
  • Open Access

Monitoring of minimal residual cancer in bone marrow in high-risk breast cancer patients treated with high-dose chemotherapy

  • ,
  • 2,
  • 1,
  • 1,
  • 3,
  • 4,
  • 3,
  • 5,
  • 6 and
  • 1
Breast Cancer Research20057 (Suppl 2) :P5.04

https://doi.org/10.1186/bcr1185

  • Published:

Keywords

  • Breast Cancer Patient
  • Epirubicin
  • Independent Predictive Factor
  • Stem Cell Support
  • Bone Marrow Change

Background

The present study aimed to investigate the clinical relevance of minimal residual cancer in breast cancer patients before and after high-dose adjuvant chemotherapy with or without progenitor stem cell support.

Methods

One hundred and eighteen high-risk stage II breast cancer patients entering the Scandinavian Study Group multicentre trial [1] were randomised to nine cycles of dose-escalated FEC (5-flurouracil, epirubicin, cyclophosphamide) or three cycles of standard FEC followed by high-dose chemotherapy. Bone marrow (BM) samples at diagnosis and 6 months after completion of chemotherapy were assessed for the presence of cytokeratin-positive (CK+) cells. CK+ cells in BM were evaluated as a prognostic and predictive marker and were compared with other defined prognostic factors of the primary tumour.

Results

Monitoring BM changes at time of diagnosis and at 6 months post-treatment is an independent predictive factor for breast cancer-specific survival (P = 0.001, univariate analysis). Those who have consistent CK-negative BM findings constitute a group of patients with good prognosis.

Conclusion

Monitoring of CK+ cells in BM before and after high-dose chemotherapy with or without stem cell support can be used clinically as a surrogate maker to predict outcome in breast cancer patients.

Authors’ Affiliations

(1)
Laboratory for Cellular Therapy, Department of Medical Oncology and Radiotherapy, The Norwegian Radium Hospital, University of Oslo, Norway
(2)
Department of Pathology, The Norwegian Radium Hospital, Oslo, Norway
(3)
Department of Medical Oncology and Radiotherapy, Ullevål University Hospital, Oslo, Norway
(4)
Department of Medical Oncology and Radiotherapy, Haukeland Hospital, Bergen, Norway
(5)
Department of Oncology, St Olavs Hospital, Trondheim University Hospital,, Trondheim, Norway
(6)
Radiumhemmet, Karolinska Institute, Stockholm, Sweden

References

  1. Bergh J, Wiklund T, Erikstein B, Lidbrink E, Lindman H, Malmstrom P, Kellokumpu-Lehtinen P, Bengtsson NO, Soderlund G, Anker G, et al: Tailored fluorouracil, epirubicin, and cyclophos-phamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study. Lancet. 2000, 356: 1384-1391. 10.1016/S0140-6736(00)02841-5.View ArticlePubMedGoogle Scholar

Copyright

© BioMed Central 2005

Advertisement